Poseida Therapeutics Inc. (PSTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PSTX Stock Price Chart Interactive Chart >
PSTX Price/Volume Stats
| Current price | $2.15 | 52-week high | $11.10 |
| Prev. close | $2.00 | 52-week low | $1.82 |
| Day low | $1.93 | Volume | 147,303 |
| Day high | $2.21 | Avg. volume | 174,657 |
| 50-day MA | $3.39 | Dividend yield | N/A |
| 200-day MA | $5.64 | Market Cap | 134.82M |
Poseida Therapeutics Inc. (PSTX) Company Bio
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
Latest PSTX News From Around the Web
Below are the latest news stories about Poseida Therapeutics Inc that investors may wish to consider to help them evaluate PSTX as an investment opportunity.
Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology InnovationsPoseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today beginning at 10:00am ET / 7:00am PT. |
Poseida Therapeutics Appoints Brent Warner as President, Gene TherapyPoseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Brent Warner has joined the Company as President, Gene Therapy effective February 21, 2022. |
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers SymposiumPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced interim results from its Phase 1 clinical trial of P-PSMA-101, the Company's solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC). These data are being presented today at the 2022 American Society of |
Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday, February 23, 2022. |
Poseida Therapeutics names company''s PresidentPoseida Therapeutics (PSTX) appoints current President and Chief Business Officer, Mark Gergen, to the role of CEO effective as of February 1, 2022 and Eric Ostertag as… |
PSTX Price Returns
| 1-mo | -27.61% |
| 3-mo | -44.01% |
| 6-mo | -68.61% |
| 1-year | -75.29% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -68.43% |
| 2021 | -37.92% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...